A+ R A-

Young Investigator Poster Sessions

Please select from the following list of abstracts, representing the presentations given in Stockholm 2008 (IWWM-5) Session 10:

The Novel Hydroxamic Acid-Derived HDAC Inhibitor, LBH589, Induces In Vitro Antitumor Activity in Waldenström’s Macroglobulinemia. Xiaoying Jia , Aldo M. Roccaro , Abdelkareem Azab , Hai T. Ngo , Antonio Sacco , Molly R Melhem , Feda Azab , Judith Runnels , Nicolas Burwick , Phong Quang , Hemanuel N. Husu,Teru Hideshima , Xavier Leleu   and  Irene M. Ghobrial . Medical Oncology, Dana-Farber Cancer Institute,  Harvard Medical School, Boston, MA, USA; Service des Maladies du Sang et Laboratoire d'Immunologie, CHRU, Lille, FRANCE.

Histone Deacetylase Inhibitors Demonstrate Significant Preclinical Activity as Single Agents, and in Combination with Bortezomib in Waldenström’s Macroglobulinemia. J.Y. Sun, L. Xu, H.Y. Tseng, B. Ciccarelli, M. Fulciniti, E. Hatjiharissi, Y. Zhou, G. Yang, X. Liu, T. Ioakimidis, P. Sheehy, R. Manning, C. Patterson, N. Munshi, O. O’Connor, S.P. Treon. Bing Center for Waldenström’s Macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; and Columbia University, New York, NY, USA.

SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenström’s macroglobulinemia. Hai T. Ngo, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Acquired von Willebrand syndrome and von Willebrand factor abnormalities in Waldenström’s Macroglobulinemia. B. Hivert, C. Caron, A. Duhamel, J. Goudemand and P. Morel, Hospitalier Schaffner, Lens, FRANCE.

Is SDF1(-801 GA) polymorphism a new genetic prognostic for survival after treatment initiation in Waldenström’s macroglobulinemia (WM)? S. Poulain S, M. Ertault, X. Leleu, V. Coiteux, J. Fernandes, L. Stalnikiewicz, P. Duthilleul, P. Morel. CH de VALENCIENNES, FRANCE, CH de LENS, FRANCE , CHRU de LILLE, FRANCE.

Toward a Proteomic Specific WM (Waldenström’s macroglobulinemia) Entity. Laurent Vallat , Aurore Perrot, Cedric Pionneau4, Frederic Jacob, Nabih Azar, Martine Brissard, Frederic Davi, François Lemoine, Lucile Musset, Hélène Merle-Béral  and Veronique Leblond  Department of Biological Hematology, Pitie-Salpetriere Hospital, France  Department of Clinical Hematology, Pitie-Salpetriere Hospital, France  Department of Immunology, Pitie-Salpetriere Hospital, France  Post-Genomic Platform P3S, Pitie-Salpetriere Hospital, University of Paris VI, France  INSERM U543, UPMC University of Paris VI, FRANCE.

Comparative Outcomes following CP-R, CVP-R and CHOP-R in patients with Waldenström’s Macroglobulinemia. Ioakimidis L, Patterson CJ, Soumerai JD, Manning RJ, Sheehy P, Treon SP.  Bing Center for Waldenström’s Macroglobulinemia, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Fludarabine based combinations are highly effective as first-line or salvage treatment for patients with Waldenström’s Macroglobulinemia. S Peinert, CS Tam, HM Prince, J Scarlett, MM Wolf, EH Januszewicz, D Westerman, JF Seymour Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, AUSTRALIA; Department of Haematology, St Vincent's Health Melbourne, Fitzroy, AUSTRALIA; Gippsland Cancer Care Centre Latrobe Regional Hospital, Traralgon, AUSTRALIA.

 

Stockholm 2008 (IWWM-5)

The 5th International Workshop on WM (IWWM-5) was made possible through the kind and generous unrestricted grants or gifts from the following sponsors:

Peter and Helen Bing Fund for Waldenström's Macroglobulinemia

 

Karen Lee Sobol Foundation

 

Bailey family Foundation for Waldenström's Macroglobulinemia

 

Linda and Edward Nelson Fund for Waldenström's Macroglobulinemia